MBX Biosciences, Inc. (MBX)Healthcare | Biotechnology | Carmel, United States | NasdaqGS
33.77 USD
+0.55
(1.656%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 33.77 Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ★★☆☆☆ |
Hot Take | April 19, 2026, 12:54 a.m. EDT
Despite a 'Strong Buy' analyst consensus and solid cash reserves, MBX faces a severe short-term headwind due to massive speculative put flow targeting a drop below $25–27. The market is clearly pricing in a correction for the recent rally. Fundamentally, the high short ratio (6.83x) and negative consensus EPS suggest the stock is in a fragile 'catch-a-fall' phase. While the long-term thesis on the obesity program is intact, the current technicals and options flow signal a sell-off before stability returns, making this a risky hold at current levels. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.117897 |
| AutoETS | 0.124604 |
| MSTL | 0.131453 |
| AutoTheta | 0.137724 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 48% |
| H-stat | 4.84 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.217 |
| Excess Kurtosis | -1.26 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.161 |
| Market Cap | 1,604,420,992 |
| Forward P/E | -8.31 |
| Website | https://mbxbio.com |
As of April 19, 2026, 12:54 a.m. EDT: Derivatives data reveals a distinct short-term hedging stance. In the Apr 17 expiration, put volume and OI massively outweigh calls (930 vs 65 vol), with heavy positioning at OTM strikes of 22.5 and 25, despite the stock sitting at 33.77. However, call OI is surprisingly concentrated at the 30 strike (OTM relative to current price, yet deep ITM compared to 52-week lows) indicating a defensive 'floor' play or volatility hedge rather than a directional pump. The April 17 ATM IV is elevated relative to the spread with further DTE, suggesting traders are pricing in a Auflösung of the current rally at the month-end. Longer-dated strikes show higher OI far below current price (e.g., 7.50 calls, 25 puts), indicating a 'range-bound' or 'double dip' positioning rather than an aggressive breakout trade.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.420157 |
| Address1 | 11,711 North Meridian Street |
| Address2 | Suite 300 |
| All Time High | 44.89 |
| All Time Low | 4.807 |
| Ask | 43.18 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 447,150 |
| Average Daily Volume3 Month | 574,535 |
| Average Volume | 574,535 |
| Average Volume10Days | 447,150 |
| Bid | 24.99 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 8.218 |
| City | Carmel |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 33.77 |
| Current Ratio | 24.623 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 35.0 |
| Day Low | 33.31 |
| Debt To Equity | 0.161 |
| Display Name | MBX Biosciences |
| Earnings Call Timestamp End | 1,754,564,400 |
| Earnings Call Timestamp Start | 1,754,564,400 |
| Earnings Timestamp | 1,773,318,600 |
| Earnings Timestamp End | 1,778,502,600 |
| Earnings Timestamp Start | 1,778,502,600 |
| Ebitda | -97,807,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -12.589 |
| Enterprise Value | 1,231,311,872 |
| Eps Current Year | -2.89169 |
| Eps Forward | -4.0616 |
| Eps Trailing Twelve Months | -2.38 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 32.3661 |
| Fifty Day Average Change | 1.4039001 |
| Fifty Day Average Change Percent | 0.043375634 |
| Fifty Two Week Change Percent | 342.0157 |
| Fifty Two Week High | 44.89 |
| Fifty Two Week High Change | -11.119999 |
| Fifty Two Week High Change Percent | -0.24771662 |
| Fifty Two Week Low | 7.2 |
| Fifty Two Week Low Change | 26.57 |
| Fifty Two Week Low Change Percent | 3.6902778 |
| Fifty Two Week Range | 7.2 - 44.89 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,726,234,200,000 |
| Float Shares | 29,029,709 |
| Forward Eps | -4.0616 |
| Forward P E | -8.314457 |
| Free Cashflow | -52,442,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 63 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02743 |
| Held Percent Institutions | 1.02553 |
| Implied Shares Outstanding | 47,510,243 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-09-13 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana. |
| Long Name | MBX Biosciences, Inc. |
| Market | us_market |
| Market Cap | 1,604,420,992 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_613097171 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -86,971,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,601,570,291 |
| Number Of Analyst Opinions | 11 |
| Open | 34.6601 |
| Operating Cashflow | -79,949,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 317 659 0200 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 33.77 |
| Post Market Time | 1,776,456,605 |
| Previous Close | 33.22 |
| Price Eps Current Year | -11.678292 |
| Price Hint | 2 |
| Price To Book | 4.109272 |
| Profit Margins | 0.0 |
| Quick Ratio | 24.255 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.549999 |
| Regular Market Change Percent | 1.65563 |
| Regular Market Day High | 35.0 |
| Regular Market Day Low | 33.31 |
| Regular Market Day Range | 33.31 - 35.0 |
| Regular Market Open | 34.6601 |
| Regular Market Previous Close | 33.22 |
| Regular Market Price | 33.77 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 302,557 |
| Return On Assets | -0.18751 |
| Return On Equity | -0.27757 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 47,510,243 |
| Shares Percent Shares Out | 0.0756 |
| Shares Short | 3,593,407 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 2,395,339 |
| Short Name | MBX Biosciences, Inc. |
| Short Percent Of Float | 0.117 |
| Short Ratio | 6.83 |
| Source Interval | 15 |
| State | IN |
| Symbol | MBX |
| Target High Price | 88.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 62.54545 |
| Target Median Price | 66.0 |
| Total Cash | 373,704,992 |
| Total Cash Per Share | 7.866 |
| Total Debt | 596,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 24.29655 |
| Two Hundred Day Average Change | 9.47345 |
| Two Hundred Day Average Change Percent | 0.38990924 |
| Type Disp | Equity |
| Volume | 302,557 |
| Website | https://mbxbio.com |
| Zip | 46,032 |